argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab
argenx (Euronext & Nasdaq: ARGX),...
Read MoreEMA has published a revision...
Read MoreIn studies of mice and...
Read MoreEthicists and medical experts in...
Read MoreTo mark the World AIDS...
Read MoreShire plc, the leading global...
Read MoreDaiichi Sankyo Company, Limited (hereafter,...
Read MoreValens GroWorks Corp., a licensed,...
Read MoreThe first pre-clinical data for...
Read MoreCobra Biologics, an international contract development...
Read More